Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2026-01-21 @ 10:20 PM
Study NCT ID:
NCT00633594
Status:
COMPLETED
Last Update Posted:
2017-01-31
First Post:
2008-03-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Sponsor:
SCRI Development Innovations, LLC
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCRI LYM 58
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None